India Diabetes Care Drugs Market

India Diabetes Care Drugs Market Size, Share & Trends Analysis Report by Drug Class (Insulins, Non-Insulin Injectable Drugs, Oral Anti-Diabetic Drugs, and Combination Drugs) Forecast, 2020-2026
    Update Available - Forecast 2024-2030   

Published: Jul 2022 | Report Code: OMR2023311 | Category : Pharmaceuticals | Delivery Format: /

India diabetes care drug market is projected to grow significantly during the forecast period. The primary factors that are driving the growth of the market include the rising prevalence of diabetes amongst the peoples across India. India has the second-largest number of adults with diabetes globally. As per the IDF, there were 77 million adults (20-79 years) suffering from diabetes in 2019. Increased stress level, sedentary lifestyles, excessive consumption of alcohol, smoking, that elevates body’s sugar levels and in turn leads to diabetes, hence, these are likely to contribute to the market growth. Further, the presence of the key players also supports the growth of the Indian diabetes care drugs market over the forecast period. 

However, the availability of alternative products such as diabetes care devices is likely to hamper the growth of the diabetes care drug market in India. India diabetes care drugs market is segmented on the basis of drug class as insulins, non-insulin injectable drugs, oral anti-diabetic drugs, and combination drugs. Insulins are amongst the most consumed and favored drug, owing to their fast- and long-action properties. 

Further, Bayer AG, Eli Lilly & Co., Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis International AG, Sanofi SA, Sun Pharmaceuticals Industries Ltd., and Takeda Pharmaceuticals Industries Ltd. are some of the prominent players operating in the Indian diabetes care drugs market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market. 

Research Methodology

The market study of the Indian diabetes care drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report is intended for diabetes care drug market players, drug manufacturing companies, investment companies, industry associations and experts, research institutes, government organizations, regulatory bodies, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

  1. India Diabetes Care Drugs Market Research and Analysis by Drug Class

The Report covers:

  • Comprehensive research methodology of the India diabetes care drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the India diabetes care drug market.
  • Insights about market determinants that are stimulating the Indian diabetes care drugs market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.

1. Report Summary

1.1. Research Methods and Tools

1.2. Market Breakdown

1.2.1. By Segments

1.2.2. By Geography

2. Market Overview and Insights

2.1. Scope of the Report

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

2.3. Rules & Regulations

3. Market Determinants

3.1. Motivators

3.2. Restraints

3.3. Opportunities

4. Market Segmentation

4.1. India Diabetes Care Drugs Market by Drug Class

4.1.1. Insulins

4.1.2. Non-Insulin Injectable Drugs

4.1.3. Oral Anti-Diabetic Drugs

4.1.4. Combination Drugs

5. Company Profiles

5.1. AstraZeneca Plc

5.2. Eli Lilly and Co. 

5.3. Johnson & Johnson Services Inc.

5.4. Merck & Co. Inc.

5.5. Mylan NV

5.6. Novo Nordisk A/S

5.7. Pfizer Inc. 

5.8. Sanofi SA

5.9. Sun Pharmaceuticals Industries Ltd.

5.10. Takeda Pharmaceuticals Industries Ltd.

5.11. Teva Pharmaceuticals Industries Ltd.

1. INDIA DIABETES CARE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)

1. INDIA DIABETES CARE DRUGS MARKET SHARE BY DRUG CLASS, 2019 VS 2026 (%)

2. INDIA INSULIN MARKET SIZE, 2019-2026 ($ MILLION)

3. INDIA NON-INSULIN INJECTABLE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)

4. INDIA ORAL ANTI-DIABETIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)

5. INDIA COMBINATION DIABETES DRUGS MARKET SIZE, 2019-2026 ($ MILLION)